Home
Mari K Halle's picture

Mari K Halle

Researcher
  • E-mailMari.Halle@uib.no
  • Phone+47 995 96 597
  • Visitor Address
    Kvinneklinikken
    Jonas Lies vei 72
    5053 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Genomic characterization and therapeutic targeting of hpv undetected cervical carcinomas. Cancers. 1-15.
  • Show author(s) 2021. A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer. 1690-1698.
  • Show author(s) 2020. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Show author(s) 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Show author(s) 2020. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Show author(s) 2019. PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Show author(s) 2019. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Show author(s) 2019. Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Show author(s) 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Show author(s) 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Show author(s) 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Show author(s) 2017. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer. 1-6.
  • Show author(s) 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) 2017. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Show author(s) 2017. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Show author(s) 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Show author(s) 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Show author(s) 2016. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumour Biology. 10697-10702.
  • Show author(s) 2016. Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 513-523.
  • Show author(s) 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Show author(s) 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Show author(s) 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Show author(s) 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Show author(s) 2014. The evolution and functional divergence of the beta-carotene oxygenase gene family in teleost fish-Exemplified by Atlantic salmon. Gene. 268-274.
  • Show author(s) 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Show author(s) 2014. Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Show author(s) 2014. Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Show author(s) 2014. Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • Show author(s) 2014. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Show author(s) 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Show author(s) 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Show author(s) 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Show author(s) 2014. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Show author(s) 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Show author(s) 2013. Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Show author(s) 2013. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 pages.
  • Show author(s) 2013. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Show author(s) 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Show author(s) 2012. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
Reader opinion piece
  • Show author(s) 2012. Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
Doctoral dissertation
  • Show author(s) 2017. Molecular alterations suggesting new treatment strategies in uterine carcinomas.

More information in national current research information system (CRIStin)